Collagen Binding Assay (CBA) is a second line test in the investigation of von Willebrand disease in order to provide further information where the disease subtype is unclear or where a collagen binding defect is suspected. CBA is performed as a semi-automated ELISA using manufactured microtitre plates coated with collagen type III. The collagen binding capacity of vWF should normally be comparable to VWF concentration in plasma (vWF antigen) and also VWF function as assessed by the ristocetin cofactor activity assay. However, occasionally, collagen binding functionality is reduced. Results should be interpreted with VWF Antigen, VWF Ristocetin cofactor activity and Factor VIII level.
Clinical Indications CBA is particularly informative when attempting to distinguish between various VWD subtypes or where collagen binding defects are suspected due to family history.
Reference Range 0.45 – 1.50 IU/mL
Sample Required 4.5 mL sodium citrate (pale blue top) adults 1.8 mL sodium citrate (pale blue top) paediatrics
Turnaround Time 14 days
All requests must be discussed with and approved by the haematology clinical team.
Please Note: Samples will be rejected if under/over-filled, clotted or haemolysed